Biologics to treat Psoriatic arthritis
Are there any other medications that may be available now or in the future to treat PsA?
Numerous novel biologic therapies for PsA are in phase III trials including: Bimekizumab (a dual inhibitor of IL-17A and IL-17F), guselkumab and risankizumab (IL-23 inhibitors), and upadacitinib (JAK inhibitor). Additional biologic and small molecule therapies with similar mechanisms of action are in phase I and II clinical trials. One such agent, remtolumab targets both IL-17 and TNFα. Namilumab, an antagonist of granulocyte macrophage colony-stimulating factor, is in studies for psoriasis and has a novel mechanism of action. Biosimilars of infliximab, adalimumab, and etanercept have all been FDA-approved.